Form 4: Glaukos Director David Hoffmeister Reports Significant Equity Compensation Grants

Glaukos Corporation Director David F. Hoffmeister reported the acquisition of restricted stock units and stock options as part of his compensation, aligning his interests with shareholders.

Summary

• Glaukos Corporation Director David F. Hoffmeister reported changes in his beneficial ownership of company securities through two distinct transactions.
• On January 2, 2025, Mr. Hoffmeister received a grant of 557 restricted stock units (RSUs) in lieu of annual director retainer fees, which are scheduled to vest in full on the one-year anniversary of the grant date.
• Subsequently, on May 29, 2025, he was granted an additional 2,108 restricted stock units and 3,149 stock options, both pursuant to the Issuer's Director Compensation Policy.
• The RSUs granted on May 29, 2025, will vest in full on their one-year anniversary, while the stock options granted on the same date have an exercise price of $94.87, vest on May 29, 2026, and are set to expire on May 29, 2035.
• Following these transactions, Mr. Hoffmeister's direct beneficial ownership of common stock increased to 6,918 shares, which includes 4,381 unvested RSUs and previously vested but deferred RSUs.
• He also beneficially owns 3,149 derivative stock options.
• A reported transfer of 3,230 shares from Mr. Hoffmeister's direct ownership to a corporation of which he is the sole stockholder resulted in no change to his overall beneficial ownership.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates routine equity compensation for a director, aligning their interests with shareholders, which is generally viewed favorably. There are no negative implications from this filing.

Positives

• The grants of restricted stock units and stock options to Director David F. Hoffmeister align his financial interests directly with those of Glaukos Corporation shareholders, promoting long-term value creation.
• The compensation is explicitly stated to be part of the Issuer's established Director Compensation Policy, indicating a structured and transparent approach to executive and director incentives.

Future Outlook

This Form 4 filing primarily reports past and future scheduled equity compensation grants and does not contain forward-looking statements regarding the company's operational or financial performance beyond the vesting and expiration dates of the granted securities.

Industry Context

This filing is a routine disclosure of insider equity compensation and does not provide specific insights into broader industry trends or competitive dynamics within the ophthalmology or medical device sector. Such compensation practices are common across various industries to align management and director interests with shareholders.

Corporate Governance

Related Party Transactions

• A transfer of 3,230 shares from the Reporting Person's direct ownership to a corporation of which the Reporting Person is the sole stockholder was reported, which resulted in no change in the Reporting Person's beneficial ownership.

Stakeholder Impact

• Shareholders: The equity grants to a director are intended to align the director's long-term interests with those of the shareholders, potentially encouraging decisions that enhance shareholder value.

Next Steps

• Vesting of 557 restricted stock units on January 2, 2026 (one-year anniversary of grant).
• Vesting of 2,108 restricted stock units on May 29, 2026 (one-year anniversary of grant).
• Vesting of 3,149 stock options on May 29, 2026 (one-year anniversary of grant).
• Potential exercise of stock options by May 29, 2035.

Key Dates

Keywords

Glaukos Corporation, GKOS, SEC Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock Units, Stock Options, Director Compensation, Equity Compensation